| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA757: Cabotegravir and rilpivirine for treating HIV-1 |
|
Medicine details |
|
| Medicine name | rilpivirine (Rekambys®) |
| Formulation | 600 mg prolonged-release suspension for injection, 900 mg prolonged-release suspension for injection |
| Reference number | 4794 |
| Indication | In combination with cabotegravir injection, for the treatment of human immunodeficiency virus type 1 (HIV‑1) infection in adults who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents of the NNRTI and INI class |
| Company | Janssen-Cilag Ltd |
| BNF chapter | Infections |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 22/12/2020 |
| NICE guidance | |